加载中
NASDAQHealthcareBiotechnology
最新数据
US$42.19
−US$0.01 · -0.02%
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
前收盘价
US$42.19
−US$0.01 · -0.02%
盘中时间采用ET。市场数据可能有所延迟。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$42.19
52周区间
当前US$42.19
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
持有
估值
30
偏贵
情绪
60
多空交织
风险
29
中等风险
动量
68
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (SMA). Another key program, SRK-181, is currently undergoing Phase 1 clinical assessment for tackling cancers that exhibit resistance to established checkpoint inhibitor treatments, including anti-PD-1 or anti-PD-L1 antibody therapies. Beyond these, the company cultivates a robust pipeline of innovative potential therapies, aiming to significantly improve the lives of individuals grappling with various severe ailments, such as neurological muscle conditions, malignancies, and fibrotic disorders. In a strategic partnership, Scholar Rock is collaborating with Gilead Sciences, Inc. to identify and develop targeted inhibitors of transforming growth factor beta (TGF-beta) activation, specifically for addressing fibrotic diseases. Established in 2012, Scholar Rock Holding Corporation operates from its headquarters in Cambridge, Massachusetts.
日内区间
当前US$42.19
52周区间
当前US$42.19
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | — | — | — | 3319.3万 USD | 1881.6万 USD |
| 销货成本 | 2.08亿 USD | 193.7万 USD | 284.4万 USD | 1.23亿 USD | 1.08亿 USD |
| 毛利 | −2.08亿 USD | −193.7万 USD | −284.4万 USD | −8985.1万 USD | −8965.2万 USD |
| 研究与开发 | 2.08亿 USD | 1.83亿 USD | 1.19亿 USD | 1.24亿 USD | 1.08亿 USD |
| 销售、一般及管理费用 | 1.76亿 USD | 6750.4万 USD | 4939.5万 USD | 4261.9万 USD | 4026.9万 USD |
| 营业费用 | 1.76亿 USD | 2.5亿 USD | 1.68亿 USD | 4451.9万 USD | 4026.8万 USD |
| 利息收入 | 1390万 USD | 1268.2万 USD | — | — | — |
| 利息支出 | 689.3万 USD | 683.7万 USD | — | — | — |
| 折旧和摊销 | 165.8万 USD | 193.7万 USD | 284.4万 USD | 298.6万 USD | 262.7万 USD |
| 营业利润 | −3.85亿 USD | −2.52亿 USD | −1.71亿 USD | −1.34亿 USD | −1.3亿 USD |
| 净利润 | −3.78亿 USD | −2.46亿 USD | −1.66亿 USD | −1.35亿 USD | −1.32亿 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$70.45
上涨空间 66.98%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.95亿0.01%2.3万亿 USD0.03%US$381.94+0.63%
iShares Russell 2000 ETFIWM1.24亿0.16%787.4亿 USD0.19%US$278.94+0.49%
State Street SPDR S&P Biotech ETFXBI7797.5万0.79%98.74亿 USD0.35%US$153.77+3.00%
Vanguard Extended Market ETFVXF6567.84万0.07%954亿 USD0.05%US$235+0.80%
iShares Russell 2000 Growth ETFIWO4102.59万0.30%139.17亿 USD0.24%US$356.78+0.94%
Vanguard Russell 2000 ETFVTWO3650.5万0.20%180亿 USD0.06%US$112.66+0.50%
iShares Biotechnology ETFIBB3247.76万0.31%108.2亿 USD0.44%US$206.49+3.00%
Schwab U.S. Small-Cap ETFSCHA2294.48万0.11%218.24亿 USD0.03%US$32.79+0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMState Street SPDR S&P Biotech ETFXBIVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOiShares Biotechnology ETFIBBSchwab U.S. Small-Cap ETFSCHAAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
